Gumokimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Gumokimab
- ak 111
- AK-111
- ak111
- AK111
- gumokimab
- Gumokimab
- gumokimab [INN]
- Gumokimab [WHO-DD]
- gumokimab inn
- gumokimab who dd
- immunoglobulin g1 anti human interleukin 17a human mus musculus monoclonal ak111 gamma 1 chain disulfide with human mus musculus monoclonal ak111 kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 17A) (HUMAN-MUS MUSCULUS MONOCLONAL AK111 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL AK111 .KAPPA.-CHAIN, DIMER
- CAS registry numbers
- 2428381-52-4
- ChEMBL ID
- CHEMBL5095302
- FDA ingredient codes (UNII)
- 6YS6C7XEC8
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- gumokimab
- Type
- Antibody
- Drug name stem
- -mab
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- IL-17A
- Gene symbol
- IL-17A
- Median affinity
- 9.29
- Affinity units
- pKd
- Condition
- Psoriasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Spondylitis, Ankylosing
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003898
- Subject identifier
- D013167
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003898
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005306
- Highest recorded phase
- 3
- NCT03622021
- NCT05096364
- NCT05504317
- NCT06061471
- NCT06066125
- NCT05467995
- NCT06378697
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (7)
- A Clinical Study of AK139 in Healthy Subjects
- A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
- A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
- A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
- A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
- To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis
In development for (2)
- Ankylosing spondylitis Phase 3
- Psoriasis Phase 3